Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2015 05:30 ET | Source: Achaogen, Inc.

Achaogen Announces Plazomicin Granted QIDP Designation by FDA

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
November 10, 2014 07:00 ET | Source: Achaogen, Inc.

Achaogen Announces Third Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
October 29, 2014 05:30 ET | Source: Achaogen, Inc.

Achaogen to Present at 2014 Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR)...
September 17, 2014 05:30 ET | Source: Achaogen, Inc.

Achaogen Announces First Patient Enrollment in a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
August 11, 2014 16:15 ET | Source: Achaogen, Inc.

Achaogen Announces Second Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
July 14, 2014 05:30 ET | Source: Achaogen, Inc.

Achaogen Appoints Dr. Ian Friedland as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
May 12, 2014 08:00 ET | Source: Achaogen, Inc.

Achaogen Announces First Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
April 07, 2014 05:30 ET | Source: Achaogen, Inc.

Achaogen to Present at 13th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
April 02, 2014 05:30 ET | Source: Achaogen, Inc.

Achaogen Appoints Chris Boerner to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
March 17, 2014 11:55 ET | Source: Achaogen, Inc.

Achaogen Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...